A Prospective, DB, Randomized, Placebo-controlled Clinical Trial of IC Infusion of Mesenchymal Precursor Cells (MPC) in the Treatment of Patients With ST-elevation Myocardial Infarction
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2018
Price : $35 *
At a glance
- Drugs Rexlemestrocel-L (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions; Therapeutic Use
- Acronyms AMICI
- Sponsors Angioblast Systems; Mesoblast
- 08 Nov 2018 This study has been completed in Poland.
- 23 Oct 2018 Planned End Date changed from 1 Jul 2018 to 1 Apr 2021.
- 21 Sep 2018 The trial has been completed in Spain.